EyePoint Q3 net revenue $1.0M, net loss $59.7M; DURAVYU Phase 3 fully enrolled; $172.5M financing

EyePoint, Inc.

2025-Q3 EPS reported -$2.35 vs consensus -$0.80 ▼ miss (-193.6%)

Q3 2025 total net revenue fell to $1.0M from $10.5M YoY; net loss widened to $59.7M ($0.85/share) vs $29.4M ($0.54/share).
Cash, equivalents & securities $204M at Sep 30; Oct public offering added $162M net, extending runway into Q4 2027.
Phase 3 LUGANO/LUCIA for wet AMD fully enrolled (>900 patients); topline data expected mid-2026, first-to-market target.
Initiated pivotal Phase 3 DME program (COMO, CAPRI) with FDA non-inferiority pathway; first dosing in Q1 2026.
Preclinical data shows DURAVYU inhibits IL-6 inflammation plus VEGF, supporting multi-target mechanism in retina.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.